Fig. 3.

Survival of mice receiving IC/RV combination therapy. NXS2 tumor-bearing mice were treated with DMSO p.t. (n = 20), 20 mg RV p.t. (n = 20), IC i.v. (n = 23), or IC/RV in combination (n = 23). Mice were observed for survival for 100 days or until their primary tumor reached the size limit (15 mm in any dimension) requiring euthanasia. Sixty-one percent of the mice receiving IC/RV combination survived to day 100 with no detectable tumors compared to 15 and 13% of the mice in the RV-alone or the IC-alone group, respectively. There was a significant difference in overall survival among the four treatment groups (P < 0.0001). Pairwise comparisons of survival distribution over time: DMSO versus RV: P = 0.005, DMSO versus IC: P = 0.19, DMSO versus IC/RV: P < 0.0001, IC/RV versus IC: P = 0.0003, IC/RV versus RV: P = 0.001, RV versus IC: P = 0.16